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Abstract
Background Body fat and/or muscle composition influences prognosis in several cancer types. For advanced gastric and gas-
troesophageal junction cancer, we investigated which body composition parameters carry prognostic information beyond
well-established clinical parameters using robust model selection strategy such that parameters identified can be expected
to generalize and to be reproducible beyond our particular data set. Then we modelled how differences in these parameters
translate into survival outcomes.
Methods Fat and muscle parameters were measured on baseline computed tomography scans in 761 patients with ad-
vanced gastric or gastroesophageal junction cancer from the phase III EXPAND trial, undergoing first-line chemotherapy.
Cox regression analysis for overall survival (OS) and progression-free survival (PFS) included body composition parameters
and clinical prognostic factors. All continuous variables were entered linearly into the model as there was no evidence of
non-linear prognostic impact. For transferability, the final model included only parameters that were picked by Bayesian infor-
mation criterion model selection followed by bootstrap analysis to identify the most robust model.
Results Muscle and fat parameters formed correlation clusters without relevant between-cluster correlation. Mean muscle
attenuation (MA) clusters with the fat parameters. In multivariate analysis, MA was prognostic for OS (P < 0.0001) but not for
PFS, while skeletal muscle index was prognostic for PFS (P = 0.02) but not for OS. Worse performance status Eastern Cooper-
ative Oncology Group (ECOG 1/0), younger age (on a linear scale), and the number of metastatic sites were strong negative
clinical prognostic factors for both OS and PFS. MA remained in the model for OS (P = 0.0001) following Bayesian information
criterion model selection in contrast to skeletal muscle index that remained prognostic for PFS (P = 0.009). Applying stricter
criteria for transferability, MA represented the only prognostic body composition parameter for OS, selected in >80% of boot-
strap replicates. Finally, Cox model-derived survival curves indicated that large differences in MA translate into only moderate
differences in expected OS in this cohort.
Conclusions Among body composition parameters, only MA has robust prognostic impact for OS. Data suggest that treat-
ment approaches targeting muscle quality are unlikely to prolong OS noticeably on their own in advanced gastric cancer pa-
tients, indicating that multimodal approaches should be pursued in the future.
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Introduction
The impact of body composition on cancer prognosis and
treatment-related adverse events is increasingly recog-
nized.1 Analysis of computed tomography (CT) scans at
the level of the third lumbar spine is considered a standard
approach to measure muscle and adipose tissue body com-
position parameters.2 Sarcopenia characterized by low mus-
cle mass and/or quality was associated both with a
decrease in overall survival (OS) and an increase in the fre-
quency and severity of toxicities in cancer patients under-
going chemotherapy, molecular targeted therapy, or
immunotherapy3 while the prognostic role of adipose tissue
parameters is controversial.4–7
Retrospective studies identified skeletal muscle index
(SMI), representing a marker for muscle mass and mean
muscle attenuation (MA), representing a marker for muscle
quality, as prognostic factors in cancer patients, analysing
large cohorts including different cancer entities and/or
cancer patients at different clinical stages.8–10 Prognostic
cut-off values were used, optimized11 for the individual
data set in question. This results in difficulties to transfer
such cut-off values between cohorts. More importantly,
using cut-values when prognosis varies linearly with the
measurement precludes quantification of the potential
impact of inducing specific differences in individual body
composition parameters on survival. Extensive research
efforts are ongoing to identify novel pharmacological
targets12 as well as applying nutritional13 and/or exercise-
based interventions14 to improve muscle mass and/or qual-
ity in cancer patients and to improve tolerability of cancer
treatment and survival outcomes. As cachexia/sarcopenia15
is common in locally advanced or metastatic gastric cancer
and adenocarcinomas of the gastroesophageal junction
(GEJ), gaining information on the amount of improvement
in a body composition parameter needed to translate into
clinically meaningful survival benefit is important for
assessing the prospect of an intervention aiming to improve
outcome.
Here, we analysed the prognostic impact of muscle and
adipose tissue body composition parameters in patients
with locally advanced or metastatic gastric cancer or adeno-
carcinomas of the GEJ from the phase 3 EXPAND trial.16
Our objectives were to understand the correlation between
distinct muscle and fat parameters as well as body mass in-
dex (BMI), to determine which body composition parame-
ters robustly correlate with OS or progression-free survival
(PFS) in conjunction with clinical parameters, and to pro-
vide a parsimonious model incorporating muscle and fat
parameters continuously such that it can be used to assess




Patients with unresectable, locally advanced, or metastatic
gastric or GEJ cancer from the EXPAND trial, which failed to
demonstrate an improvement in PFS and OS with the addi-
tion of the anti-epidermal growth factor receptor antibody
cetuximab to standard chemotherapy (capecitabine/cis-
platin),16 were studied. In this open-label, randomized, con-
trolled, phase 3 study, adults with histologically confirmed
adenocarcinoma of the stomach or GEJ with locally advanced
unresectable (M0) or metastatic (M1) disease were enrolled
at 164 sites in 25 countries worldwide.16 Inclusion and exclu-
sion criteria are provided in detail in the Supporting Informa-
tion. A total of 904 patients were randomized for treatment.
Of these, 802 baseline CT scans (89%) were evaluable for our
analysis of body composition parameters. The reason for this
difference is related to the fact that in EXPAND, there was an
independent radiological review of CT scans as quality control
for PFS. In rare cases, magnetic resonance imaging was used.
The first tumour assessment imaging was scheduled after 6
weeks corresponding to two cycles of treatment. Patients
without available baseline CT consist of those few imaged
with magnetic resonance imaging and those who progressed
or died before the first tumour assessment. In the later cases,
there was no point in providing the baseline images to the in-
dependent reviewer. Thus, our study population excludes de
facto early treatment failures before 6 weeks. Therefore, the
analysis population is slightly favourably selected with a me-
dian OS of 10.8 months as compared with 10.2 months in
the intent-to treat population. The core analysis population
comprises n = 761 patients with complete measurements
and key clinical data (CONSORT diagram, Figure S1). The
study was performed according to the principles of the Dec-
laration of Helsinki, and translational research was approved
by local/national ethics committee.
Measurement of body composition parameters
Two adjacent cross-sectional CT images at the level of the
third lumbar vertebra were analysed by two readers (K. L.
and L. J.) who were blinded to clinical data. Segmentation
of CT data was performed using a custom made and recently
published software tool.17 Briefly, the tool starts by standard-
izing the thickness of CT slices to 1 mm. Next, density ranges
190 to 30 Hounsfield units (HU) and 29 to 150 HU for
adipose and muscle tissue, respectively, are defined.8,9,18
During segmentation, the individual regions of interest are
selected manually yielding areas of total adipose tissue
(TAT) and visceral adipose tissue (VAT) as well as areas of
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ventral abdominal muscle (Mven), spinal muscle (Mspi), and
psoas muscle (Mpso), as illustrated in Figure S2. Area of sub-
cutaneous adipose tissue (SAT) was calculated by the differ-
ence of TAT and VAT. Total muscle area was determined as
sum of Mven, Mspi, and Mpso. Additionally, intermuscular
adipose tissue (IMF) was identified between muscle groups
and beneath the muscle fascia of the Mpso and the dorsal
spine musculature. Mean muscle attenuation (MA) was mea-
sured in HU based on the total muscle area at the third lum-
bar vertebra of the same CT images. All parameters were
defined in the two adjacent CT slices, and mean values were
used for further analysis. Reproducibility of results between
the two readers was assessed by analysing CT data sets from
50 subjects randomly selected from the EXPAND cohort. An
intra-observer coefficient of variation of <1.3% was required,
consistent with other reports in the literature.8,9
Statistical analysis
Because no statistically significant differences in PFS or OS be-
tween treatment arms were found in EXPAND, all patients
(n = 904) irrespective of the treatment arm were included if
baseline CT scans were available. Analysis of normalized
muscle/adipose tissue areas and MA was carried out on the
original scale. We used Pearson’s correlation coefficients to
analyse correlation among parameters. For survival analysis
(PFS and OS), standard Cox regression analysis relying on
the proportional hazard assumption was used. Adipose tissue
parameters and the well-established muscle parameters MA
and SMI together with key clinical parameters were studied
in order to investigate whether the measurements carry addi-
tional information beyond standard clinical information. With
the exception of BMI, all metric parameters including age
(lower age was associated with unfavourable prognosis)
could be modelled linearly as we carefully checked martingale
plots for indication of non-linearity and used modelling with
fractional polynomials to investigate whether using a non-
linear transformation significantly improved the model (data
not shown). In particular, there was no evidence of natural
cut-off values.
In a separate set of analysis, anatomic muscle areas nor-
malized for body size were used to replace SMI in the models
(i.e. Mven area, Mspi area, and Mpso area) to determine if
they carry a prognostic role superior to SMI as a parameter
of muscle mass on an exploratory basis.
We started the variable selection process with univariate
analyses and a full multivariate model including all parame-
ters considered. Next, Bayesian information criterion (BIC)
was used to select a parsimonious model. Finally, robustness
of the model selection and the transportability of results was
assessed by generating n = 1000 bootstrap replicates of the
data (sampling randomly with replacement from the original
data set). Covariates selected in at least 80% of the bootstrap
samples19 were included in the final model. For purpose of il-
lustration, Cox model-derived survival curves were generated
for covariate constellations of interest: ECOG (0/1), and MA
and age fixed at their 20% and 80% quintiles, respectively.
Finally, interaction between clinical prognostic parameters




Characteristics of the 761 patients are given in Table 1. Four
percent of patients had locally advanced unresectable dis-
ease; all other patients had metastatic disease. Median age
was 59 years (range 18–84). At baseline, 60% of patients
were normal weight, 23% overweight, 8% obese, and 9% un-
derweight according to BMI categories. The majority of pa-
tients (75%) was male. Eighty-three per cent of patients
suffered from gastric cancer, while 17% were diagnosed with
GEJ cancer. Forty percent of patients were from Asia, and
60% from non-Asian regions in the world (Table 1).
Body composition parameters
Body composition parameters at baseline by clinically defined
subgroups are also summarized in Table 1. VAT significantly
increased with age and with increasing BMI categories.
Female patients showed slightly lower VAT values compared
with male patients. Asian patients were characterized by
significantly lower VAT values compared with non-Asian
patients. Patients with an ECOG performance status 0 com-
pared with 1 were characterized by significantly higher SMI
and Mspi muscle parameters. SMI and Mspi increased with
higher BMI, while MA decreased significantly. There was no
correlation between MA and ECOG performance status (PS)
(data not shown). Asian patients showed higher MA values
compared with non-Asian patients, and the same was true
for male compared with female patients.
Correlations between body composition
parameters
Correlation between muscle parameters and BMI was weak.
In contrast, adipose tissue-related parameters (TAT, SAT,
and VAT) showed strong positive correlations between each
other and with BMI. MA was negatively correlated with adi-
pose tissue parameters TAT, SAT, VAT, and IMF (Figure 1
and Table S1).
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Prognostic role of body mass index
Expectedly, there was evidence of non-linearity in BMI when
looking at survival differences between BMI categories: Pa-
tients with a BMI <18.5 kg/m2 and BMI >30 kg/m2 showed
decreased survival rates at 12 months (25.6% and 22.5%, re-
spectively) as compared with the BMI groups 18.5–25 and
25–30 kg/m2 (44% and 48.4%, respectively), log rank test, P
= 0.0264 (Figure S3). In the Cox model-based univariate and
multivariate analyses, BMI (on any scale) was not prognostic
for OS or PFS (Tables 2 and 3).
Univariate analysis of body composition and
clinical parameters
Adipose tissue-related parameters lacked prognostic impact.
SMI as a measure of muscle mass was only weakly prognostic
for OS (P = 0.026), while MA was highly prognostic (P <
0.0001; Table 2). For PFS, both MA and MSI were prognostic
(P = 0.016 and P = 0.010, respectively; Table 2). ECOG PS was
strongly prognostic in the log rank test, P < 0.0001, and rep-
resented the strongest clinical prognostic parameter for both
PFS and OS (P < 0.0001, each) together with the number of
metastatic sites (P < 0.0001 and P = 0.005, respectively) ac-
cording to the Cox model-based univariate analysis (Table 2).
Multivariate analysis of body composition and
clinical parameters
ECOG PS (0/1) and age (on a linear scale) were strongly prog-
nostic (P < 0.0001, each) for OS and for PFS (P < 0.0001 and
P = 0.0007, respectively). The number of metastatic sites was
the only additional clinical parameter of prognostic influence
for OS (P = 0.005) and PFS (P < 0.0001), while ethnic group
(Asian vs. non-Asian) was not prognostic (Table 3). SMI (P =
0.02) was prognostic for PFS, while MA (P = 0.046) almost
lacked prognostic impact. In contrast, MA again was strongly
prognostic for OS (P < 0.0001), while SMI was not (Table 3).
Table 1 Baseline characteristics and muscle/fat parameters
n (%) VATa SMI Mspia MA
ECOG PS
1 360 (47) 34.24 60.36 18.39 45.77
0 401 (53) 37.59 62.17 19.06 45.91
ns P = 0.00872 P = 0.00024 ns
Age
<65 571 (75) 32.81 61.12 19.06 47.31
≥65 190 (25) 45.62 61.94 18.22 41.27
P < 0.0001 ns P = 0.0012 P < 0.0001
BMI
<18.5 69 (9) 7.3 53.68 16.30 50.36
18.5–25 458 (60) 25.71 60.12 18.74 47.64
25–30 171 (23) 64.61 65.94 19.82 41
>30 63 (8) 83.99 67.57 19.63 36.88
P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
Sex
Female 189 (25) 31.83 54.44 16.91 43.30
Male 572 (75) 37.38 63.60 19.49 46.68
P = 0.011 P < 0.0001 P < 0.0001 P < 0.0001
Metastatic sites
≥2 295 (39) 39.38 61.65 18.81 44.05
1 466 (61) 33.87 61.12 18.87 46.98
P = 0.00837 ns ns P < 0.0001
Site
Gastric 621 (81) 34.43 61.09 18.84 46.53
GEJ 127 (17) 43.70 62.73 19.03 42.92
Unknown 13 (2) 36.19 58.87 17.79 41.70
P = 0.0149 ns ns P < 0.00063
Liver metastasis
Yes 351 (46) 41.26 62.18 19.10 44.95
No 410 (44) 31.51 60.60 18.64 46.61
P < 0.0001 P = 0.0188 P = 0.051 P = 0.0137
Ethnicity
Asian 307 (40) 29.07 59.50 18.83 49.40
Non-Asian 454 (60) 40.69 62.56 18.87 43.44
P < 0.0001 P < 0.0001 ns P < 0.0001
BMI, body mass index; GEJ, gastroesophageal junction; Mspi, spinal muscle; ns, not significant; SMI, skeletal muscle index; VAT, visceral
adipose tissue.
aNormalized for body size: area (cm2)/size (m2).
U.T. Hacker et al.
DOI: 10.1002/jcsm.12484
Journal of Cachexia, Sarcopenia and Muscle 2020; 11: 135–144
138
Bayesian information criterion model selection and
bootstrap analysis
Following BIC selection in order to select a parsimonious
model, SMI dropped out as a prognostic marker for OS, while
MA was confirmed (P < 0.0001) in this model together with
ECOG, age, and the number of metastatic sites (Table 4).
No interaction was found between clinical parameters and
MA in this model. For PFS, BIC selection resulted in a model
composing of SMI, ECOG, and the number of metastatic sites
(Table 3). Finally, only three prognostic parameters were
reproduced for OS in more than 80% of n = 1000 bootstrap
replicates: ECOG, age, and MA (P < 0.0001, each; Table 4).
For PFS, only ECOG and the number of metastatic sites were
reproduced. An analysis using anatomical muscle areas
(Mpso, Mven, and Mspi) instead of MSI indicated that this
did not lead to a more differentiated model. Interestingly,
Mpso was selected in the BIC model for PFS but like SMI,
failed to be selected in more than 80% of n = 1000 bootstrap
replicates (Tables S2 and S3).
Figure 1 Graphical correlation matrix of body mass index (BMI) and fat/muscle-related body composition parameters. Green lines indicate positive
correlations; blue lines indicate negative correlations. Thickness of line indicates strength of the correlation (corresponding numerical values: see
Table S1). Mpso, psoas muscle; Mspi, spinal muscle; Mven, ventral abdominal muscle; SAT, subcutaneous adipose tissue; SMI, skeletal muscle index;
TAT, total adipose tissue; VAT, visceral adipose tissue.
Table 2 Univariate analysis overall survival and progression-free survival
Covariates
Overall survival Progression-free survival
HR 95% CI P-value HR 95% CI P-value
ECOG (0/1) 1.523 1.3–1.784 <0.0001 1.416 1.185–1.691 <0.0001
Age 0.991 0.984–0.999 0.022 0.994 0.985–1.002 0.142
Male versus female 0.799 0.666–0.958 0.016 0.821 0.67–1.007 0.059
Asian versus non-Asian 1.223 1.039–1.223 0.016 0.976 0.815–1.169 0.795
Number met. sites (1 vs. ≥2) 1.258 1.07–1.479 0.005 1.405 1.173–1.682 <0.0001
BMI 1.006 0.986–1.026 0.569 1.006 0.984–1.028 0.605
MA 0.984 0.975–0.992 <0.0001 0.988 0.978–0.998 0.016
SMI 0.99 0.981–0.999 0.026 0.987 0.977–0.997 0.01
VATa 1.001 0.998–1.004 0.389 1.002 0.999–1.005 0.175
SATa 1.002 0.999–1.004 0.204 1.001 1.185–1.691 0.454
BMI, body mass index; CI, confidence interval; HR, hazard ratio; SAT, subcutaneous adipose tissue; SMI, skeletal muscle index; VAT, visceral
adipose tissue.
aNormalized for body size: area (cm2)/size (m2).
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Cox model-based illustration of the prognostic
impact of parameters
Survival curves derived from the final robust Cox model for
OS (Table 4) modelled for individual constellations of prog-
nostic factor values, representing the 20% and 80% value of
quintiles for MA, age, and ECOG (0/1), indicated a median
OS of 7.5 months for age 46 years, MA 38.6 HU, and ECOG
1 as compared with 15.5 months for age 67 years, MA 53.5
HU, and ECOG 0 (Figure 2).
Model-derived survival curve of the parameter MA on its
own, again representing 20% and 80% value of quintiles, indi-
cates a median OS of 9.7 months for MA 36.8 HU compared
with 11.4 months for MA 53.3 HU (Figure S4).
Discussion
Several studies have demonstrated the influence of low mus-
cle mass (sarcopenia) and/or poor muscle quality (low
radiodensity) on cancer prognosis,8–10 reporting prognostic
cut-off values based on the statistical method of optimal
stratification11 for respective parameters. Optimizing a cut-
value by minimizing the P-value, however, can lead to bias,
namely, an overestimation of the prognostic impact as the
cut-offs so determined heavily dependent on the case mix
in the respective study populations, for example, according
to age, gender, ethnicity, cancer type, and stage, and conse-
quently cannot be applied uniformly in different cohorts as
exemplified by considerable different cut-off values reported
in an Asian cohort4 compared with North American cohorts.8–
10 In addition, defining a low-risk group and a high-risk group
based on a cut-value is conceptually misleading if the prog-
nostic impact is in fact linear: It falsely suggests that there
are two qualitatively different subgroups, although in reality,
the hazard just varies proportional to the measurement. Ac-
cordingly, and as all body composition parameters as well
as age were best modelled linearly in our data set, we used
Cox regression analysis to investigate whether body composi-
tion parameters carry prognostic information beyond well-
established clinical parameters.
We furthermore aimed to identify which parameters can
be expected to generalize and to be reproducible beyond
our particular data set, as such parameters need to be consid-
ered when building conceptual models with respect to inter-
ventions aiming at improving body composition parameters
to improve cancer care. Consequently, we choose to apply
Table 4 Bayesian information criterion selected multivariate Cox model for overall survival and progression-free survival and number of bootstrap
replicates
Overall survival
Covariates HR 95% confidence interval P-value Bootstrap selected (%)
ECOG (0 vs. 1) 1.523 1.300–1.784 <0.0001 99.6
Age 0.984 0.984–0.999 <0.0001 93.6
MA 0.975 0.975–0.992 <0.0001 92
Number met. sites (1 vs. ≥2) 1.258 1.070–1.497 0.005 56.5
Progression-free survival
ECOG (0 vs. 1) 1.421 1.188–1.7 <0.0001 92.4
Number met. sites (1 vs. ≥2) 1.476 1.231–1.77 <0.0001 91.3
SMI 0.987 0.977–0.997 0.009 62.4
HR, hazard ratio; SMI, skeletal muscle index.
Table 3 Multivariate analysis overall survival and progression-free survival
Covariates
Overall survival Progression-free survival
HR 95% CI P-value HR 95% CI P-value
ECOG (0/1) 1.551 1.319–1.823 <0.0001 1.403 1.17–1.682 <0.0001
Age 0.983 0.975–0.002 <0.0001 0.987 0.978–0.997 0.007
Male versus female 0.929 0.736–1.174 0.539 0.879 0.675–1.145 0.34
Asian versus non-Asian 1.169 0.978–1.398 0.086 0.919 0.755–1.118 0.397
Number met. sites (1 vs. ≥2) 1.269 1.076–1.496 0.005 1.451 1.206–1.745 <0.0001
BMI 1.009 0.96–1.06 0.732 1.028 0.967–1.092 0.379
MA 0.979 0.968–0.991 <0.0001 0.987 0.975–1 0.046
SMI 0.99 0.978–1.003 0.129 0.983 0.969–0.997 0.02
VATa 1.001 0.996–1.007 0.566 1.004 0.999–1.01 0.133
SATa 0.997 0.992–1.003 0.309 0.995 0.989–1.001 0.092
BMI, body mass index; CI, confidence interval; HR, hazard ratio; SAT, subcutaneous adipose tissue; SMI, skeletal muscle index; VAT, visceral
adipose tissue.
aNormalized for body size: area (cm2)/size (m2).
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a robust model selection strategy (BIC model selection
followed by bootstrap analysis) for transferability beyond
multivariate analysis.
Muscle and adipose tissue parameters formed distinct
clusters showing more or less stringent correlations with
BMI (Figure 1 and Table S1), supporting the view, that individ-
ual body composition parameters may allow a more differen-
tiated modelling of prognostic impact compared with the
global parameter BMI. As BMI does not distinguish muscle
from adipose tissue or describes adipose tissue distribution,
it was suggested that measures of body composition param-
eters beyond BMI represent a superior approach (reviewed
in Caan et al.20). In our analysis, BMI was only weakly prog-
nostic in the log rank test and lacked prognostic impact in
the Cox regression analyses (Figure S3 and Tables 2 and 3).
This is in accordance with recently published data from a
smaller cohort of metastatic gastric or GEJ cancer patients
where BMI also lacked prognostic impact.21
As expected, gender, age, and ethnic background were sig-
nificantly related to differences in muscle and adipose tissue
parameters (Table 1).22–24 Specifically, Asian compared with
non-Asian patients were characterized by markedly lower
VAT and markedly higher SMI and MA values (Table 1). Be-
cause sarcopenia-related parameters SMI and MA have been
identified as promising prognostic markers in cancer patients
(reviewed in Bozzetti3), the better overall prognosis reported
for Asian gastric cancer patients compared with non-Asian
patients25 may at least in part be related to a more
favourable body composition in Asian patients. In support
of this hypothesis, ethnicity in contrast to MA was not prog-
nostic for OS or PFS in multivariate analysis (Table 2).
On univariate and multivariate analyses for PFS and OS, all
adipose tissue parameters lacked prognostic power. This adds
to the controversial data published on the role of adipose tis-
sue parameters for cancer prognosis.4–7 SMI as a global pa-
rameter for muscle mass was prognostic for PFS in
univariate and multivariate analyses (P = 0.01 and P = 0.02,
respectively), but not for OS (P = 0.026 and P = 0.129, respec-
tively). In contrast, MA as a parameter of muscle quality was
strongly prognostic for OS in univariate und multivariate anal-
yses (both P < 0.0001) but only very weakly for PFS (P =
0.016 and 0,046, respectively; Tables 2 and 3). It is still under
debate whether parameters of muscle quantity (SMI) or qual-
ity (MA) are better suited as prognostic factors.3 Specifically,
in a non-small cell lung cancer cohort, MA was prognostic for
OS, while SMI was not.26 The same was true in a cohort of
pancreatic cancer patients undergoing surgery.27
Furthermore, in a very recent study in n = 88 advanced
gastric and GEJ cancer patients, neither baseline SMI nor
MA was prognostic for PFS or OS.21 As there are significant
differences in patient characteristics, compared with our data
set, they may most likely account for the differences. Overall,
a growing body of evidence exists, demonstrating that muscle
mass, as represented by SMI, influences the efficacy of
Figure 2 Cox model-derived survival curves generated for covariate constellations of interest: ECOG PS (0/1), MA, and age fixed at their 20% and 80%
quintiles, respectively. OS, overall survival.
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chemotherapy in different cancer entities, which may very
well explain the prognostic role for PFS found in our cohort.
On the other hand, MA is increasingly recognized as a prog-
nostic factor, in line with our findings.3
Additionally, we analysed muscle parameters according to
distinct anatomical regions (Mspi, Mpso, and Mven) for their
prognostic role. Overall, these parameters were not superior
compared with SMI (Table S2). Interestingly, Mpso was the
anatomic muscle parameter remaining in the model following
BIC selection and thus seems to perform similar to SMI as a
prognostic marker for PFS. While the Mpso was proposed
as a sentinel for sarcopenia, this assumption, however, has
recently been questioned.28,29
With respect to the clinical parameters, ECOG PS (0/1),
the number of metastatic sites, and age (on a linear scale)
were prominent prognostic factors both for OS and PFS in
multivariate analysis (Table 3). Interestingly, younger age
was related to worse OS. This is in contrast to large epide-
miological studies in advanced gastric cancer,30,31 reporting
improved survival outcomes in younger patients. These data
sets, however, are less homogeneous, and no studies are
available, entering age linearly into prognostic models. With
respect to ECOG PS, a similar trend has recently been re-
ported in a cohort of advanced gastric cancer patients
(ECOG 0 and 1).32
Next, BIC was used to select a parsimonious model consis-
tent with our exploratory approach. This resulted in a model
composing of the clinical parameters ECOG, age (P < 0.0001
each), and the number of metastatic sites (P = 0.005)
together with MA (P < 0.0001) as prognostic factors for OS
(Table 4). Finally, in the bootstrap analysis, ECOG, age, and
MA were selected in >80% of 1000 replicates further
confirming the robustness of these parameters (Table 4).
No interaction between clinical prognostic parameters and
MA was found in this model, underscoring the independent
prognostic role of MA in this model.
Interestingly, following this strategy, for PFS, only clinical
parameters ECOG and the number of metastatic sites were
selected in >80% (Table 4).
Cox model-based simulation of survival curves
representing 20% and 80% value of quintiles for age and
MA and including ECOG resulted in combined prognostic
groups with a median OS ranging from 7.5 months for the
worst prognostic group to 15.5 months for the best prog-
nostic group (Figure 2). This robust model demonstrates
that MA has a prognostic role in conjunction with age (on
a linear scale) and ECOG PS (0/1) in a homogeneous cohort
of fit advanced or metastatic gastric cancer or GEJ cancer
patients undergoing first-line chemotherapy. The model-
derived survival curves for MA alone representing 20% and
80% value of quintiles show that a difference of 14.7 HU
(38.6 vs. 53.3 HU) translates into a median OS difference
of only 1.7 month (9.7 vs. 11.4 months, Figure S4). Of
course, our data do not prove a causal relation between
MA and survival. However, because of the large improve-
ments in MA needed to translate into survival benefits, they
suggest that single pharmacological, nutritional, or exercise-
based treatment approaches targeting muscle quality are
unlikely to prolong OS noticeably on their own in advanced
stage gastric cancer patients. For example, 12 weeks of re-
sistance exercise training in healthy elderly resulted in only
a moderate increase in MA of 5.5 ± 1.8%.33 It can be spec-
ulated that this finding may also account for other tumour
entities associated with rapidly developing cachexia related
to aggressive tumour characteristics and overall short sur-
vival times. Consequently, multimodal approaches should
be pursued in future clinical trials as an adjunct to effective
cancer treatment in advanced stage cancer patients. It is im-
portant to add that in early stage cancers with an overall
good prognosis like in breast cancer, modification of body
composition by exercise training represents a very promis-
ing approach to improve clinical outcomes.10,34
Because distinct cancer treatments were shown to nega-
tively affect muscle parameters35,36 while others37 even im-
proved muscle mass or quality, studying the influence of
cancer treatments on muscle mass and quality during treat-
ment represents another important field of future research,1
which could easily be integrated into clinical trials, and MA
represents a robust, promising parameter in this respect.
Conclusions
Among body composition parameters, MA has a robust prog-
nostic role in conjunction with ECOG (0/1) and age for OS
contributing to an easy to assess prognostic model for previ-
ously untreated advanced gastric and GEJ cancer patients in
good PS. SMI has a prognostic role for PFS in conjunction with
ECOG (0/1) and the number of metastatic sites; however, this
parameter is less robust. Single treatment approaches
targeting muscle quality are unlikely to prolong OS noticeably
on their own in advanced gastric cancer. Findings support the
development of multimodal approaches to target
sarcopenia/muscle quality in advanced stage cancer patients.
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